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5Introductory note and acknowledgements
In-depth reviews of topical interest are published as ‘Selected issues’ each year. These reports are based on information 
provided to the EMCDDA by the EU Member States and candidate countries and norway (participating in the work of the 
EMCDDA since 2001) as part of the national reporting process.
The most recent issues selected are:
• Drug offences: sentencing and other outcomes;
• polydrug use: patterns and responses.
All ‘Selected issues’ (in English) and summaries (in 23 languages) are available on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/selected-issues
The EMCDDA would like to thank the following for their help in producing this ‘Selected issue’:
• the heads of reitox national focal points and their staff;
• the services within each Member State that collected the raw data;
• the members of the Management Board and the Scientific Committee of the EMCDDA;
• the publications office of the European Union.
Reitox national focal points
reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU 
Member States, norway, the candidate countries and at the European Commission. Under the responsibility of their governments, the 
focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at: 
http://www.emcdda.europa.eu/about/partners/reitox-network
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Introduction
Injecting drug use has a long history in Europe but it was 
in the early 1980s, with the rapid growth of intravenous 
heroin use and the spread of the human immunodeficiency 
virus (HIV), that this behaviour gained prominence as a core 
element of Europe’s drug problem. not only did injecting 
levels increase dramatically during the 1980s and 1990s (1), 
many European countries also saw a rapid increase in the 
number of HIV infections among drug users, resulting in 
increased numbers of deaths due to AIDS. The failure of 
existing prevention and treatment interventions to respond 
adequately to this problem became increasingly apparent. 
As a consequence, many European countries started to 
develop new approaches, which included making services 
more attractive and easy to access, increasing the availability 
of substitution treatment and investing in, what were then, 
innovative approaches such as needle and syringe exchange 
programmes. The objective of reducing drug-related harms, 
in particular HIV transmission, was added to national drug 
policies, alongside the existing objectives of preventing drug 
use and treating drug dependence. 
Thirty years after its spread, injecting drug use, which has 
been associated with more than a hundred thousand deaths 
and even more HIV and hepatitis C virus (HCV) infections 
in Europe, remains at the heart of the drug problem in this 
part of the world. This ‘Selected issue’ looks at the current 
situation in injecting drug use. overall, two questions guide 
the report: What are the prevalence and trends in injecting 
drug use in today’s Europe? And, how do European countries 
try to prevent or reduce this type of drug use and the harms 
associated with it? These questions are addressed in an 
analysis of trends in injecting drug use and morbidity and 
mortality associated with injecting drug use. Finally, the main 
interventions designed to prevent or reduce the injection of 
drugs or to reduce the harms associated with drug injecting 
are reviewed in the context of the available evidence 
regarding their effectiveness.
(1) Countries in eastern and central Europe experienced the ‘heroin epidemic’ somewhat later.
Injecting and other modes of drug administration
Drugs may be taken orally, whether by drinking, swallowing 
or chewing. Intranasal forms of consumption include inhaling 
the vapour of a heated drug (chasing), spraying dissolved 
drug into the nose, or snorting a drug in powder form. 
Smoking is another way of administering drugs, whereby 
the fumes of burning drugs are inhaled into the lungs. Lastly, 
drugs can be injected with hypodermic needles into veins, 
under the skin or into muscle. 
The speed with which a drug is absorbed and metabolised 
depends on the route of administration. Drugs taken orally 
are absorbed slowly, while those taken intranasally enter the 
blood more rapidly through the mucous membranes of the 
nose. Smoking and injecting provide the fastest absorption, 
leading to a larger amount of drug getting into the brain more 
rapidly. For example, snorting heroin gives users a ‘high’ in 
10–15 minutes, whereas users can feel the effect of heroin 
about seven seconds after smoking it or injecting it into a 
vein. With most drugs, those who inject become dependent 
faster than users with other routes of administration.
The type of drug available may influence the route of 
administration. For example, two forms of heroin exist on the 
illicit drugs markets in Europe: the commonly available brown 
heroin (a chemical base form), which comes mainly from 
Afghanistan; and the less frequent white heroin (a salt form), 
which typically originates from south-east Asia. Brown heroin 
cannot be snorted, but it can be smoked and chased (inhaling 
the heroin vapour), and it can be dissolved in hot water with 
acid and injected. White heroin, on the other hand, can 
easily be snorted up the nose in powder form; it can also be 
dissolved in cold water without additives and injected, but it 
can be only very inefficiently smoked or chased. 
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Prevalence and trends in injecting drug 
use in Europe
This report analyses data from a variety of sources to 
estimate prevalence and trends in drug injecting in Europe. 
national estimates of the number of injecting drug users were 
available for 14 countries. Data from drug treatment centres 
were also used for this assessment, as they are collected 
according to a standardised methodology and include 
reports from most countries. The section ends with information 
on injecting drug use from non-treatment settings, consisting 
of selected country examples and data from prison settings 
and infectious disease studies among injecting drug users.
Sources of information on injecting drug use
As injecting drug use is a hidden phenomenon, practised by 
a very small proportion of the population, reliable information 
on its prevalence is not accessible by standard survey 
methods (Wiessing et al., 2008b). Instead, information must 
be gathered on specific sub-populations and by using indirect 
indicators of injecting drug use. 
Indirect estimates of injecting drug users can be derived 
from observable segments of the population, for example 
drug users in treatment, by using methods such as capture–
recapture (1). The EMCDDA problem drug use indicator 
collects such estimates of the prevalence of injecting drug 
use (2). Although many European countries are unable to 
provide national estimates of injecting drug use routinely, and 
methods often differ between countries, compared with other 
regions of the world, estimates in Europe are more complete, 
and have better quality and comparability (Mathers et al., 
2008).
Data on drug users entering treatment in European countries 
are reported to the EMCDDA each year, and provide the 
most comprehensive available statistics on the prevalence of 
injecting drug use in Europe (3). While these data refer only to 
a sub-group of drug users, those entering treatment, they do 
allow comparisons between countries and over time. 
Surveys on blood-borne infectious diseases, such as HIV, 
among drug injectors are a further source of information on 
the prevalence, incidence and trends in injecting drug use. 
The proportions of young and new drug injectors among 
those surveyed for infectious diseases can act as indicators of 
recruitment into drug injecting.
prison populations typically report higher than average 
prevalence levels of drug use, both in prison and before 
imprisonment, and this includes elevated levels of injecting. 
Studies carried out in prisons can provide important insights 
into injecting behaviour among otherwise hard-to-reach 
sections of the population. 
Heroin injecting, alone or in combination with the use of 
other substances, is the cause of death in the majority of fatal 
accidental overdoses reported in European countries. The 
EMCDDA collects data on such fatalities with the drug-related 
death indicator, which can act as an indirect indicator of the 
prevalence and trends in drug injecting. 
European countries have been responding to drug injecting 
in various ways since the problems it causes first became 
apparent. The EMCDDA is collecting data on treatment 
and harm reduction responses. As well as documenting the 
national responses to injecting drug use, these data can 
be used to identify commonalities and differences in the 
approaches of Member States, and may help to explain 
trends in injecting use and its consequences over time. 
(1) See national prevalence guidelines on the EMCDDA website for 
more information on methods.
(2) problem drug use is defined as ‘injecting drug use or long-
duration/regular use of opioids, cocaine and/or amphetamines’.
(3) See ‘Treatment demand indicator — an overview of the 
methods and definitions used’ in the 2009 statistical bulletin for more 
information.
Prevalence estimates of injecting drug use
Fourteen countries were able to provide national estimates 
of the prevalence of injecting drug use (Figure 1) for 2002 
or later. The available estimates range from less than one 
to 15 injecting drug users per thousand population aged 
15–64, suggesting considerable differences in prevalence 
between countries. For the twelve EU Member States with 
prevalence estimates, the weighted average is about 
2.5 cases per 1 000 population aged 15–64 (2). This 
figure, if extrapolated to the whole European Union, would 
correspond to between three quarters of a million and one 
million active injecting drug users.
(2)  The weighted average is 0.25 %, with an uncertainty range (weighted averages of lower and upper limits of the country estimates) of 0.22 % to 0.30 %, 
resulting in an estimate of 859 000 (753 000–1 019 000) for 2008. This estimate must be considered with caution as it is based on data available from only 
12 of the 27 EU Member States.
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The lack of data and, in some cases, wide confidence 
intervals make drawing conclusions on time trends in the 
prevalence of injecting difficult. Five countries were able to 
provide data for successive years (Figure 2). The estimates 
for the United Kingdom show a significant decrease in the 
prevalence of injecting drug use between 2004 and 2006. 
Statistically significant time trends were not detected in the 
other four countries. 
Injecting drug use among clients entering treatment
Data collected on drug users entering treatment provide the 
most complete and up-to-date picture of injecting drug use 
across Europe (3). on entering treatment, drug users are 
asked to declare the usual route of administration of their 
Figure 1: Estimates of the prevalence of injecting drug use (cases per 1 000 population aged 15–64)
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nB:   A horizontal mark indicates a point estimate; a vertical mark indicates an estimation uncertainty interval: a 95 % confidence interval or one based on 
sensitivity analysis. Methods of estimation are indicated: Cr, capture–recapture; TM, treatment multiplier; Tp, truncated poisson; CM, combined methods; 
MM, mortality multiplier; oT, other methods. Target groups may vary slightly owing to different methods and data sources; therefore, comparisons should be 
made with caution. For germany, a central estimate was not available; a midpoint was calculated as the simple average of the low and high estimates. For 
portugal, the interval represents the lowest and highest bounds of the two available samples, and the point estimate a simple average of the two. For norway, 
an additional estimate is available (method oT, 2006, central estimate: 5.3, range 4.2–6.2). However, as it is derived by a method not recommended by 
the EMCDDA, the presented estimate is considered to be more reliable. For Finland and Estonia, rates have been adjusted to 15–64 from the original age 
ranges of the studies of 15–54 and 15–44 respectively. For Estonia, the upper limit of the confidence interval is off-scale (37.9 per 1 000).
  For more information on the data, see Table pDU-102 (part ii) in the 2009 statistical bulletin.
Sources: reitox national focal points. 
(3) See ‘Treatment demand indicator: collecting and interpreting data on drug users in treatment’, p. 10.
primary drug during the last 30 days. They are also asked if 
they are currently (at least once in the last 30 days) or have 
ever injected any substance, regardless of whether the drug 
injected is the primary or secondary drug. 
The description of prevalence presented here is based on all 
clients who entered drug treatment in 2007 in 26 European 
countries (24 EU Member States, Croatia and Turkey). 
Data were not available for Estonia, poland, portugal and 
norway. The description of trends is based on the clients 
who entered treatment for the first time between 2002 
and 2007. It should be noted that the prevalence data 
reported here refer only to treatment entrants, and may not 
be representative of injecting prevalence in the total treated 
population. 
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Figure 2: Trends in the prevalence of injecting drug use (cases per 
1 000 population aged 15–64)
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nB:   Data for countries providing national estimates of injecting drug use 
for the period 2002 to 2007. See Table pDU-102 (part ii) in the 2009 
statistical bulletin for further details.
Sources: reitox national focal points.
Treatment demand indicator: collecting and 
interpreting data on drug users in treatment
The treatment demand indicator provides statistics on the 
treated population in Europe under three main categories: first 
treatment demands, all treatment demands, and all clients in 
treatment. ‘First treatment demands’ (or first treatment entries) 
refers to clients who report never having entered treatment 
before. This group can provide a window on recent trends 
in drug use, as it is likely to include those in the treated 
population who started injecting most recently. ‘All treatment 
demands’ represents all clients who entered treatment in a 
given year, including those entering for the first time. Finally, 
‘all treatment’ consists of all clients who were in treatment in 
a given year, regardless of whether they entered treatment in 
that year or were already in treatment since an earlier year. 
This group includes most drug users in long-term treatment, 
such as opioid substitution. Data on all clients in treatment 
are still limited and not regularly collected, but a pilot study 
carried out in 14 countries (1) showed that the proportion of 
injectors is usually highest in this group, although depending 
on primary drug and country (2). 
Differences in the reported prevalence of injecting among the 
three groups of treated drug users may provide insights into 
changing trends in drug use. For example, a low prevalence 
of injecting among opioid users entering treatment for the 
first time combined with a higher prevalence among all 
opioid users entering or already in treatment might indicate a 
decreasing trend of injecting among new opioid users. Thus, 
when interpreting data on drug users in treatment, it should be 
kept in mind that the prevalence of injecting depends on the 
group assessed. Furthermore, data on treatment entries cannot 
be extrapolated to the whole population of treated drug users 
and may not be representative of the wider population of 
drug users, which includes those not in treatment.
(1) For information on the study, see EMCDDA (2009b) p. 20. 
(2) See Table TDI-38 in the 2009 statistical bulletin.
one-third (33%) of all drug clients entering treatment in 2007 
reported injection as the usual route of administration of 
their primary drug. However, the proportion of those ‘usually 
injecting’ their primary drug varies greatly between countries, 
from under 2 % in the netherlands to 93 % in Lithuania (4).
In addition to the clients entering treatment who reported 
current drug injecting, about a quarter of those entering drug 
treatment reported having injected drugs in the past. Across 
the 24 countries providing information (5), an average of 
26 % of clients entering drug treatment in 2007 reported past 
but not current drug injecting, ranging on a national level 
from 0.3 % in Malta to 63 % in romania (Figure 3). Thus, 
about 60 % of drug treatment clients are currently injecting or 
have injected drugs in the past. 
As injecting drug use in Europe is mostly linked to opioid use, 
the level of injecting among drug users entering treatment 
is largely associated with the proportion of opioid users 
entering treatment. on average, 45 % of those entering 
treatment for primary opioid use reported currently injecting 
the drug (Figure 4). In 14 of the 26 reporting countries, more 
than half the opioid clients reported injecting the drug. The 
(4) See Table TDI-5 (part iv) in the 2009 statistical bulletin.
(5) Data were not available from Estonia, Latvia, Lithuania, poland, portugal and norway. 
lowest proportion of current injectors among primary opioid 
users entering treatment is reported by Denmark (2 %), with 
Belgium, Spain, France and the netherlands also reporting 
levels of injecting below 25 %. The highest levels of injecting 
among opioid clients are reported from countries that entered 
the European Union in 2004 or later, with injecting reported 
by 97 % of opioid clients in Lithuania, and by more than 
90 % of opioid clients in Latvia and romania. The type of 
heroin available on the market, prices and other factors, as 
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Figure 3: Current and past injecting drug use among users of any drugs entering treatment
0
20
40
60
80
100
N
et
he
rla
nd
s
H
un
ga
ry
Fr
an
ce
Sp
ai
n
Tu
rk
ey
Be
lg
iu
m
D
en
m
ar
k
Ire
la
nd
C
yp
ru
s
U
ni
te
d 
Ki
ng
do
m
A
us
tri
a
Eu
ro
pe
an
av
er
ag
e
Sl
ov
ak
ia
Sw
ed
en
C
ro
at
ia
Sl
ov
en
ia
M
al
ta
Ita
ly
G
re
ec
e
Ro
m
an
ia
C
ze
ch
 R
ep
ub
lic
G
er
m
an
y
Fi
nl
an
d
Bu
lg
ar
ia
Lu
xe
m
bo
ur
g
%
Current injectors Ever but not current injectors
nB:   Data on drug treatment entrants in 2007 or most recent year available. Current injectors reported having injected a drug during the 30 days before entering 
treatment. Former injectors reported having injected a drug at some time in their lives, but not in the 30 days before entering treatment.
Sources: reitox national reports 2008.
well as some methodological differences in data collection 
might explain some of the variations between countries. 
The prevalence of injecting among stimulant users differs by 
drug: cocaine is not commonly injected, while the opposite 
is true for amphetamines (including methamphetamine). 
Among cocaine clients entering treatment in 2007, a 
relatively small proportion (8 %) reported usually injecting 
the drug. In the three countries with a high number (over 
10 000) of clients entering drug treatment for primary 
cocaine use, the proportion of injectors among all primary 
cocaine users ranged from 0.1 % in the netherlands to 6 % 
in Italy. Conversely, a number of countries in Europe have 
long-established amphetamine problems and amphetamine 
(6) See Table TDI-5 (part iv) in the 2009 statistical bulletin.
users are an important part of the treatment population. 
Among amphetamine users entering drug treatment in these 
countries, injecting the drug is common. Thus, in the four 
countries where primary users of amphetamine (Finland, 
Sweden) or methamphetamine (Czech republic, Slovakia) 
form the largest group (between 40 % and 80 %) of 
treatment entrants, injecting is reported as the usual means 
of administration by between 41 % and 83 % of primary 
amphetamine or methamphetamine clients (6).
Use of other drugs, such as hypnotics, sedatives, 
hallucinogens and volatiles, among clients entering treatment 
is rare, and the injection of those drugs is seldom reported. 
12
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Figure 4: Injecting as the main route of administration among opioid users entering treatment
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nB:   Data on drug treatment entrants in 2007 or most recent year available. European average based on data from 26 countries; data for germany are based 
not only on the primary drug.
Sources: reitox national reports 2008.
Time trends in injecting among treatment entrants
Yearly data on drug users entering treatment for the first 
time provide useful insights into potential new trends of drug 
injecting in the wider drug using population. However, data 
are not available in all countries for longer periods, and 
changes in some countries in both data coverage and the 
reporting systems have taken place over time.
Among clients who between 2002 and 2007 entered 
treatment for the first time for opioids, cocaine or 
amphetamines, the proportion who reported injecting their 
primary drug has decreased in most countries. Among 
heroin users entering treatment for the first time, the decline 
in proportion of injectors was statistically significant in ten 
countries. only Bulgaria and Slovakia buck the trend with 
statistically significant increases (7). However, some countries 
report an increasing number of heroin injectors entering 
treatment for the first time.
(7)  Data for Bulgaria and Slovakia cover the years 2003 to 2007, during which the proportion of injectors among first time heroin clients in Bulgaria increased 
from 67 % to 74 % and in Slovakia from 77 % to 84 %. In both countries, the number of injectors declined over the period.
(8) See Table TDI-113 in the 2009 statistical bulletin.
(9) See Table TDI-5 (part i) and (part iii) in the 2009 statistical bulletin, and Table TDI-4 (part ii) in the 2005, 2006, 2007 and 2008 statistical bulletins.
In countries where a large proportion of drug clients (e.g., 
Finland, 51 %; Denmark, 21 %) reported opioids other than 
heroin (e.g., buprenorphine, misused methadone, painkillers) 
as the primary reason for entering treatment (8), drug 
injecting among first time opioid clients remained stable or 
decreased slightly between 2002 and 2007. 
Among primary cocaine users who entered treatment for the 
first time, the proportion of drug injectors also decreased in 
most countries during the period 2002–07. However, both 
the number and the proportion of first time cocaine clients are 
low in many countries. The exceptions are Spain, where they 
make up 58 % of first time clients, the netherlands (29 %) 
and Italy (26 %). Injecting is reported by few of the first time 
cocaine clients in these three countries (under 1 % in Spain 
and the netherlands, and about 5 % in Italy). A stable trend 
in injecting can be observed among users of amphetamines 
entering treatment for the first time, with small variations by 
country and by year (9).
13
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Other sources of information on injecting drug use
Selected country studies 
Studies of drug users sampled from non-treatment settings 
generally confirm the decline in drug injecting among opioid 
users across Europe suggested by the treatment data (10). 
This report looks at recent trends whereas, in a number of 
countries with long-established and historically relatively 
severe opioid problems, the decline in new injecting is 
observable from as early as the late 1980s and most 
observable during the 1990s. 
For example, the netherlands has observed a large decline 
in injecting since the 1980s. Drug users participating in the 
Amsterdam Cohort study between 1986 and 1998 reported 
both increasing cessation of injecting and decreasing 
initiation into injecting. Besides individual factors, ecological 
factors, especially changes in drug use culture and the 
drug market, were probably important in this change (van 
Ameijden and Coutinho, 2001). The incidence of injecting 
drug use among young problem drug users remains low 
(2.1 per 100 person-years in a cohort study by Buster et al., 
2009) in this country. 
Spain also reported a sharp decline in the number of 
injectors admitted to first treatment in the 1990s (Bravo et 
al., 2007). A study of heroin seizures and treatment data 
suggests that this trend may be related to an increase in 
inhalation of heroin vapour (chasing) paralleling an increase 
in the availability and purity of brown heroin, which unlike 
white heroin is suitable for this means of administration (de 
la Fuente et al., 1996). In provinces where white heroin 
predominated, most users injected, but with the gradual 
disappearance of white heroin, many heroin users switched 
to chasing. In regions where heroin was almost exclusively 
available in the brown form of the drug, a higher purity 
was associated with a larger proportion of users who were 
chasers (de la Fuente et al., 1996). This suggests that users 
may adjust their route of administration depending on the 
type and purity of the drug available. 
In France, studies show that initiation of heroin use has 
become increasingly associated with snorting; and injecting 
drug use now appears to occur at a later stage of the drug 
using career than it did in the past. There are, however, 
signs pointing to a possible increase in injecting among 
some groups of young drug users in France, as revealed by 
ethnographic research.
(10) Most of the reported studies’ samples are of users of low-threshold facilities or users arrested by the police.
(11) See the EMCDDA website for more information on the key indicator on drug-related infectious diseases. 
(12) See Table DUp-2 in the 2009 statistical bulletin. 
Injecting drug users tested for infectious diseases
Seroprevalence studies carried out as part of infectious 
disease surveillance may also provide information on drug 
injection (11). The data are collected by the EMCDDA using 
standardised instruments and include breakdowns by age and 
years of injecting. The proportion of young (under 25) or new 
(injecting for less than two years) drug users in these samples 
of tested injecting drug users may be considered to reflect 
changes in the composition of the underlying population of 
injectors, reflecting patterns of injecting initiation. 
new injecting drug users make up less than 10 % of injectors 
sampled in ten Member States, but in three countries (Czech 
republic, Lithuania, Turkey) their proportions are much 
higher (above 20 %), suggesting higher levels of initiation 
in recent years (Figure 5). Young injecting drug users (under 
age 25) account for less than 20 % of injectors sampled 
in eleven Member States, but more than 40 % of injectors 
sampled in the Czech republic, Estonia, Latvia, Lithuania, 
Austria, romania and Slovakia. Most of the countries that 
report higher proportions of young injectors experienced the 
introduction of heroin use later than elsewhere in Europe. 
However, these differences in proportions have to be 
interpreted with caution due to the limitations of the data. The 
samples have been recruited in different settings, e.g. drug 
treatment versus low-threshold services, which may come in 
contact with users earlier in their drug using career. There 
are also differences in mortality or migration among the drug 
users sampled. 
Prison studies
Injecting drugs in prison is an important public health problem, 
as it is often associated with high levels of needle sharing due 
to the limited availability of sterile needles in prisons. At least 
two documented HIV outbreaks in prisons were related to 
needle sharing (e.g. Caplinskas and Likatavicius, 2002; Taylor 
et al., 1995). Despite being places where injecting drug 
users can experience serious health risks, prisons also provide 
an important opportunity for intervention, as imprisoned 
drug users can be treated for their drug dependence and be 
provided with healthcare and other services. 
Studies reported to the EMCDDA on drug use among 
prison inmates across Europe show a lifetime prevalence of 
injecting in different countries ranging from 6 % to 38 % of 
inmates, with half of the countries (six out of twelve) reporting 
figures of over 10 % (12). Injecting within prison is reported 
by between 1 % and 31 % of inmates, depending on the 
14
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Figure 5: percentage of new and of young injectors reported in samples of injecting drug users tested for HIV or HCV
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nB:    n.a. — data not available. Young injectors are those under 25 years; new injectors are those injecting for less than two years. Samples are of injectors reported 
from studies on infectious disease (HIV and HCV). The latest available sample for each country during the period 2005–07 has been used, subject to there 
being at least 100 injectors, except for: Latvia (n = 93), netherlands (n = 56), Slovakia (n = 88) and Turkey (n = 38). Data are from 2003 for the Czech 
republic and Latvia and from 2004 for Spain and Turkey. For more information, see Table pDU-105 (part i) and (part ii) in the 2009 statistical bulletin.
Sources: reitox national focal points. 
country, with studies from five countries (out of nine) finding 
a self-reported prevalence of injecting while being in prison 
of at least 10 % (13). This shows that many inmates are or 
have been injecting drug users and that a relatively high 
proportion of injecting drug users may continue to inject in 
prison.
Injecting risk behaviours and health consequences 
of injecting drug use
Several types of injecting behaviours are practised by 
injecting drug users that put them at risk of contracting 
infectious diseases. Sharing of needles and syringes is 
strongly associated with a risk of blood-borne infections, 
such as HIV and hepatitis B and C viruses (girardi et al., 
1990; Marmor et al., 1984; Titti et al., 1988). Moreover, 
there is increasing evidence that the type of syringes injectors 
use is also associated with infection risk (gyarmathy et al., 
(13) See Table DUp-4 in the 2009 statistical bulletin. 
2009; Zule and Bobashev, 2009). Sharing other injecting 
equipment such as cookers, filters or rinse water and ‘front/
backloading’ may also be a potential source of infections 
in some populations (grund et al., 1990; gyarmathy et al., 
2009; Hagan et al., 2001). Furthermore, injecting without 
others present may increase the risk of fatal overdose. 
HIV trends in Europe
HIV infection represents one of the most serious health 
consequences of injecting drug use and one that poses 
a threat not only to drug users themselves but also to 
their sexual partners and the general population. newly 
diagnosed and reported HIV cases provide an important 
picture of the epidemiological trends in HIV infection among 
drug users (ECDC, 2009; Wiessing et al., 2008a), although 
the data should be interpreted with caution as they can be 
confounded by testing patterns and reporting delays. 
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In the countries of the European Union, the rates of reported 
newly diagnosed cases of HIV infection among injecting 
drug users are mostly at stable and low levels, or in decline. 
In some Member States (Estonia, Latvia, portugal), however, 
the data suggest that HIV transmission related to injecting 
drug use may still be occurring at relatively high rates, even 
if these rates are now declining in Estonia and portugal. 
Among countries neighbouring the European Union, 
increasing rates of reported HIV cases attributed to injecting 
drug use suggest high levels of ongoing transmission 
(ECDC, 2009; Wiessing et al., 2008a).
Trends in drug-induced deaths in Europe
Drug-induced deaths are the major cause of death among 
problem drug users (14). Data collected with the drug-related 
deaths indicator show that, in the European Union, 35 % to 
100 % of the reported drug-induced deaths in 2007 were 
related to opioids (mainly heroin). As the majority of heroin 
deaths are related to injection, this indicator may allow 
inferences about prevalence and trends in injecting drug use. 
Between 2000 and 2003, the number of reported drug-
induced deaths decreased in 21 of the 24 countries reporting 
data, and the total decreased by 23 % from 8 275 to 6 350. 
This trend was reversed in the following years, when 16 of 
the 24 countries reported an increase in drug-induced deaths 
between 2003 and 2005, with the total number of deaths 
rising from 6 350 to 6 887 (+ 8.5 %) (Vicente et al., 2009). 
Data for 2007 show that the trend in the number of drug-
induced deaths is stable in five out of 18 EU Member States, 
but is rising in 13 of these countries.
In most countries, the mean age of drug-induced deaths is in 
the mid-thirties, and in many instances it has been increasing 
steadily for more than ten years. This reflects an ageing 
cohort of problem drug users in many countries, and suggests 
that the number of young heroin users is stabilising or even 
falling. The ageing cohort is consistent with a decrease in 
the number of deaths reported in drug users under the age 
of 25 in many countries. nonetheless, in some countries, the 
sustained numbers of overdose deaths reported in drug users 
under the age of 25 suggest that there is still recruitment of 
young drug users, particularly heroin injectors.
Interventions targeting injecting drug use
European countries have targeted injecting drug use and 
its consequences with a variety of interventions. The most 
important of these has been drug treatment, in particular 
opioid substitution treatment which, besides helping users 
to stabilise or lessen their drug use, is the most effective 
intervention in reducing — if not stopping — injecting. 
(14)  Drug-induced deaths are also called ‘poisonings’ or ‘overdoses’. For more information on drug-related deaths and mortality, see the key indicator page.
Both opioid substitution and drug-free, or abstinence-based, 
modalities are available in all EU Member States, Croatia 
and norway. The availability of the various treatment 
modalities varies geographically in terms of accessibility 
and coverage. national experts, surveyed by the EMCDDA 
(2009a), estimated that substitution treatment is available to 
at least half of the opioid users in 16 countries. In the same 
countries, drug-free modalities are the preferred choice 
for 10–25 % of opioid users. In a further ten countries, 
substitution treatment is estimated to be available to a 
minority of opioid users, either because drug-free options are 
preferred, especially for younger or first-time clients, or due to 
difficulties in gaining access to substitution treatment. 
For those injectors for whom treatment is not a viable option 
or only a partial solution, other interventions such as needle 
and syringe exchange programmes aim to reduce the risk 
of infectious diseases associated with sharing injecting 
equipment. 
Becoming an injecting drug user
Seeking a greater effect of the drug by injecting was the 
reason most often cited by injectors when they were asked to 
identify why they started injecting. other reasons mentioned 
included curiosity about the effect of injecting, pleasure-
seeking, peer pressure, perceived cost savings of injection 
over other routes of administration, as well as coping with 
emotional problems, a positive effect on reputation by 
injecting or simply having the possibility to inject. 
Social network and social environment characteristics, more 
specifically, the influence of sex partners, friends or family 
members were among the strongest and most consistent 
predictors for the initiation of injecting in formal analyses of 
the factors associated with initiation. However, the exact role 
of social network members is unclear. Few injecting drug 
users reported having been alone during their first injection 
episode, and the most frequent initiator was a friend or 
acquaintance. This underlines the act of initiation as a mostly 
social event. 
Among the individual characteristics, younger age seems to 
be one of the strongest risk factors. An important predictive 
factor for injecting initiation was an increase of drug use 
prior to initiation, especially a higher frequency and amount 
of heroin use, which in the studies reviewed was most often 
reported to be the drug first injected. Higher amount and 
frequency of use are indicators of a higher degree of drug 
tolerance, which is a marker for dependence. 
nB:  This box is based on an unpublished systematic literature review 
(Stellamans, 2008) to assess factors related to transitioning to 
injecting drug use.
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Interventions to reduce drug injecting:  
opioid substitution treatment
In the European Union, opioid substitution treatment, mostly 
with methadone or buprenorphine, is the most widely used 
treatment for opioid addiction (EMCDDA, 2009a). Having 
been studied over several decades in different parts of the 
world, methadone maintenance treatment constitutes the most 
thoroughly evaluated form of treatment for drug dependence. 
A relatively robust evidence base supported by data from 
treatment outcome studies and controlled trials exists for 
the effectiveness of methadone and other drug substitution 
treatments in treating dependence on heroin and other 
opioids (Committee on the prevention of HIV Infection among 
Injecting Drug Users in High-risk Countries, 2007; gossop, 
2006; Kimber et al., 2010). 
In the context of the AIDS epidemic among heroin injectors, 
much of the research on the role of drug dependence treatment 
as an HIV-prevention strategy has focussed on the effectiveness 
of methadone maintenance treatment. Methadone 
maintenance treatment was found to reduce opioid use, 
increase rates of retention in treatment, reduce the proportion 
of drug users who inject and lead to reduced levels of HIV risk 
behaviours, such as reductions in frequency of injection or in 
sharing injecting equipment (Darke et al., 2005; gossop et 
al., 2004; gowing et al., 2008; Kelley and Chitwood, 2004). 
outcomes were mediated by other variables of methadone 
treatment, e.g. lower rates of HIV infection were associated 
with higher methadone doses and longer duration of treatment 
(Farrell et al., 2006; gossop, 2006). The extent of reductions 
in injecting-related risks was found to depend also on the level 
of co-use of other injectable drugs such as cocaine or other 
stimulants (gowing et al., 2008).
In 2007, the total number of clients in substitution treatment 
in the European Union was estimated to be around 650 000, 
which is about 40 % of the estimated total number of problem 
opioid users. The level of provision, however, is not uniform 
across Europe. Estimates from ten countries where data are 
available show that between 5 % (Cyprus) and more than 
50 % (germany) of problem opioid users may have access 
to opioid substitution treatment (see Figure 6). Especially 
in countries where opioid use is more recent, substitution 
treatment may not be available in all treatment centres, 
and where it is available access may be more restricted. 
Furthermore, many injectors may not yet have progressed 
to a level of problematic use that requires them to seek 
treatment. Thus, differences in treatment coverage may partly 
reflect differences in the average time since onset and the 
need for treatment between different populations of drug 
users (nordt and Stohler, 2008).
Figure 6: opioid substitution treatment clients as a percentage 
of the estimated number of problem opioid users
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nB:    The graphic shows the estimated or reported number of opioid maintenance 
clients as a proportion of the number of problem opioid users, estimated 
by various methods, in each country with available data. A horizontal 
mark indicates a point estimate; a vertical mark indicates an estimation 
uncertainty interval. For further information, see Figure HSr-1 in the 2009 
statistical bulletin.
Sources: reitox national focal points.
(15)  See Table HSr-11 in the 2007 statistical bulletin for trends in methadone treatment in the EU countries and norway from 1993 to 2005 and Table HSr-3 in the 
2009 statistical bulletin for the estimated number of clients in methadone treatment and of clients receiving any opioid substitution in 2003 to 2007.
The numbers receiving substitution treatment in 2007 
represent a more than three-fold increase since 1995, 
when just over 200 000 opioid users received this form 
of treatment. once substitution treatment is approved as a 
regular treatment modality, an ongoing increase in client 
numbers can be noted (15). In recent years, some Member 
States have shown a stable or even declining trend. In 
Spain, for example, the number of substitution treatment 
clients reached about 90 000 in 2002, decreasing to about 
82 000 in 2007. This trend is possibly associated with a 
decrease in heroin use among drug users during the same 
period. 
Interventions to reduce harms related to drug 
injecting: needle and syringe programmes
providing drug users with access to sterile injecting 
equipment is an important measure in reducing the harms 
associated with drug injecting. The primary goal of needle 
and syringe programmes is to reduce the spread of 
blood-borne diseases, particularly HIV. In addition, these 
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programmes aim to increase access to treatment and harm-
reduction services, provide information and advice on safer 
injecting drug use and make contact with hard-to-reach 
populations. overall, the available evidence supports the 
efficacy and cost-effectiveness of this intervention (Committee 
on the prevention of HIV Infection among Injecting Drug Users 
in High-risk Countries, 2007; ritter and Cameron, 2006; 
Kimber et al., 2010). 
needle and syringe programmes exist in all EU Member 
States, Croatia and norway, and have high availability 
in most countries. The main types of needle and syringe 
programmes are those linked to specialist drugs agencies 
(available in all countries, except in northern Ireland and 
Sweden). Subsidised or free syringes are provided in 
pharmacies in eleven EU Member States and Croatia, and 
syringe machines are in use in seven countries. Because 
incarceration may be a significant risk factor in the continued 
spread of infectious diseases among injecting drug users, 
syringe exchanges have been established in prisons in five 
EU countries (16).
The availability of syringe exchange programmes is 
considered good in 15 countries, where national experts 
estimate that needle and syringe programmes (all types, 
including pharmacy-based programmes) reach the 
majority of injecting drug users. In eleven countries (17), 
however, experts estimate that national needle and syringe 
programmes do not reach the majority of injectors. 
For countries that monitor clients of needle and syringe 
programmes at drug agencies, the coverage of these 
interventions can be calculated. The proportion of the 
estimated population of injecting drug users in contact with 
these needle exchange outlets varies from 10–15 % in 
romania, to 45 % in France, with Lithuania reporting about 
20 % and Slovenia 40 % (18). In the Czech republic, 70 % of 
the estimated population of problem drug users are in contact 
with the network of low-threshold agencies, although not all 
of those clients are injecting drug users or use the facilities to 
exchange syringes.
Distribution of syringes by street outreach workers and mobile 
units has been shown to access hard-to-reach populations 
(Coyle et al., 1998), especially in locations where drug 
injecting is highly stigmatised (ritter and Cameron, 2006). 
outreach, in general, appears to help expand service 
provision quickly in the early stages of a heroin epidemic. 
Such outreach services are an important part of syringe 
programmes in eight countries (Bulgaria, Croatia, Estonia, 
Hungary, Latvia, Slovakia, poland, portugal), most of which 
have experienced recent heroin epidemics. In these countries, 
the number of mobile syringe programmes is equal to or 
higher than the number of syringe exchange programmes 
operating at fixed locations. 
Interventions to prevent, delay, and reverse 
transitions to drug injecting
Three studies evaluating interventions to prevent, delay and 
reverse transitions to injecting drug use (1) were identified by 
j. Kimber in an unpublished survey of the English-language 
scientific literature. Two of them, both without control groups, 
looked at interventions that targeted current injectors, aiming 
to discourage their social modelling to non-injectors and to 
encourage them to adopt other routes of administration. The 
brief motivational intervention ‘Break the cycle’ developed 
by Hunt and colleagues in England (Hunt et al., 1998) 
was delivered to injecting drug users in a single prevention 
session, during which the concept of social modelling was 
explained and their skills to resist requests to initiate new 
injectors were improved. The study reported that after the 
intervention, participants were less likely to inject in front 
of non-injectors and to initiate drug users into injecting. 
The second study, conducted by Dolan and colleagues 
in Australia (Dolan et al., 2004), evaluated a cognitive 
behavioural treatment intervention encouraging injectors 
to shift to other routes of administration. The study reported 
an increase of participants using non-injecting routes of 
administration at each follow-up. Despite such positive results, 
the evidence for the effectiveness of this type of intervention 
was considered insufficient by the researchers, who called for 
further research to better understand their impact. 
The third study, a randomised controlled trial, was conducted 
in new York in 1986–88 (des jarlais et al., 1992) and aimed 
to increase participants’ resilience to transitioning to injecting. 
It examined the effect of an HIV and drug injection prevention 
programme among current heroin sniffers and found a modest 
effect at follow-up after 9 months (15 % of the experimental 
group and 33 % of the control group had started to inject), 
but it was concluded that most persons at risk would need a 
more intensive intervention.
(1) A ‘transition’ is defined as the initiation or resumption of injecting drugs.
(16)  needle and syringe programmes have been reported in prisons in germany, Spain, Luxembourg, portugal and romania; see Table HSr-4 in the 2009 
statistical bulletin.
(17)  Bulgaria, Estonia, Ireland, Italy, Latvia, Hungary, Austria, poland, romania, Slovakia and Sweden. needle and syringe programmes do not exist in Turkey, 
and the first and still unofficial programme in Cyprus was reported as having a very low level of use. Expert estimates of the availability of needle and syringe 
programmes in Malta and Croatia were not available.
(18)  For further information on numbers of clients and client contacts at needle and syringe programmes see Table HSr-5 (part ii) in the 2009 statistical bulletin. 
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In the Czech republic, needle and syringe exchange 
programmes are complemented by the distribution of gelatine 
capsules intended mainly for pervitin users (19).
Provision of syringes and estimated coverage 
of needle and syringe programmes
The number of syringes provided through needle and syringe 
programmes increased between 2005 and 2007 in most of 
the 20 countries for which data are available. Between 2003 
and 2007, the total number of syringes distributed increased 
by 33 % in the 14 countries able to provide information (20). 
Continuous increases during this period were reported from 
Belgium, Bulgaria, the Czech republic, Estonia, Hungary, 
Austria, portugal, Slovakia and Finland, while decreases 
were reported from Spain, Lithuania, Luxembourg and 
poland. Syringe provision at Latvian needle and syringe 
programmes remained at low levels during this time.
By combining data on the number of syringes distributed with 
estimates of the number of injectors, it is possible to calculate 
the number of syringes distributed per estimated injecting 
drug user (Wiessing et al., 2001). Sufficient data exist for 
this calculation to be made for twelve countries. In five of 
the countries, specialised needle and syringe programmes 
provided more than 140 syringes per estimated injector per 
year, while they operated at much lower levels elsewhere 
(see Figure 7). on average, and not including pharmacy 
sales, specialised syringe provision outlets distribute about 
50 syringes a year per estimated injecting drug user across 
the European Union (Wiessing et al., 2009). These data 
should be interpreted with caution, but they suggest that 
specialised needle and syringe programmes, even if currently 
available in almost all Member States, have varying levels of 
coverage.
To estimate the overall availability of sterile syringes, it is 
necessary to include those sold through pharmacies. For 
example, in the Czech republic the number of syringes 
sold through pharmacies increased the national estimate 
of syringe availability by about one-third to 202 syringes 
per injecting drug user per year. overall, the total need of 
syringes for an average injector depends on factors such as 
the average frequency of personal re-use and the average 
injecting frequency, which are linked with the severity of the 
dependence and the types of drugs used.
Due to their role within treatment and harm-reduction 
responses and their increasing coverage, opioid substitution 
treatment programmes and low-threshold agencies with 
needle and syringe programmes provide useful opportunities 
to gain access to drug injectors as well as to non-injectors. 
For example, staff at low-threshold facilities (including those 
without needle and syringes programmes) may promote 
non-injecting routes of administration, or discourage social 
modelling by injectors to those at risk (21). In addition, 
individual counselling on infectious disease risk and 
personalised assessment of risk behaviours also exist in all 
European countries. 
Overall findings
The most recent data, notably those provided by drug 
treatment clients, point to injecting drug use remaining stable 
or declining in most European countries. Concomitant with 
the declines in injecting drug use that have been observed 
in some countries, non-injecting routes of administration 
(smoking, chasing) have become more popular among 
heroin users. 
The data indicate also that there is still a large population 
of drug injectors in Europe and that, in some countries, new 
recruitment into injecting drug use may still have been high 
Figure 7: Syringes distributed through specialised programmes, 
per estimated injecting drug user per year
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nB:   A horizontal mark indicates a point estimate; a vertical line indicates 
an estimation uncertainty interval. The estimates of injecting drug users 
and the number of syringes distributed are for the same year, which 
is 2007 except for Estonia and Latvia (2004), Hungary and portugal 
(2005) and Malta, Slovakia and norway (2006). 
Sources: reitox national focal points.
(19) This targeted harm-reduction method is reviewed in Hartnoll et al. (2010). 
(20) See Table HSr-5 (part i) in the 2009 statistical bulletin. 
(21) See ‘Interventions to prevent, delay, and reverse transitions to drug injecting’, p. 17.
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in recent years. Estimates available from the 14 EU Member 
States with recent data suggest an average prevalence of 
injecting drug use of about 2.5 cases per 1 000 population 
aged 15–64. Extrapolated to the whole European Union, 
this would result in an estimate of between three quarters of a 
million and one million active injecting drug users. In prisons, 
injecting drug users are generally more prevalent than in the 
community, and some continue to inject while in custody. 
Among the treated population, current or former injectors 
still make up the majority of clients entering drug treatment in 
Europe. 
Another key observation is that the prevalence of injecting 
drug use varies widely between European countries. The 
differences observed between countries in the prevalence 
of drug injecting, and sometimes in the trends, cannot be 
easily explained. However, injecting levels are generally 
more pronounced in east European countries. Achieving a 
better understanding of prevalence and trends in injecting 
drug use in a national context may entail taking into account 
disparate influences. These may include: market factors, such 
as the type and price of drugs; cultural factors, such as norms 
and attitudes in population groups; socio-epidemiological 
factors, such as the period of onset of a heroin epidemic; and 
available treatment and intervention programmes. 
Injecting drug users remain a population at high risk of 
fatal outcomes and other health and social problems. The 
prevalence of the health consequences of injecting, such 
as HIV and hepatitis C virus (HCV) infection, show also 
wide variations between countries. However, whereas HIV 
prevalence is mostly concentrated in some countries, HCV 
prevalence is still generally high across the European Union. 
overall, rates of reported newly diagnosed HIV infection 
are generally declining or low across the European Union, 
suggesting that recent transmission through injecting drug 
use is generally low. Both HIV prevalence and rates of 
reported newly diagnosed cases in injecting drug users are 
lower in the European Union than in many non-EU countries, 
especially those in eastern Europe. Drug overdose deaths, 
another serious public health consequence of injecting drug 
use, have recently started to increase in Europe after years of 
decline. 
Measures such as opioid substitution treatment and needle 
and syringe programmes, which aim to reduce injecting-
related harms, now reach many of those who need them. 
Estimates suggest that more than one in three problem opioid 
users in Europe are in substitution treatment. of the different 
large-scale interventions in Europe, this type of treatment 
has probably had the most impact on reducing injecting 
prevalence. opioid substitution treatment has been shown 
in several large and well-designed studies to strongly reduce 
injecting drug use (by between a factor of three and seven). 
Many studies have also consistently found that giving out 
sterile injecting equipment results in a reduced frequency of 
self-reported injecting risk behaviours such as sharing and re-
use of needles and syringes. on average, and not including 
pharmacy sales, it is estimated that specialised syringe 
provision outlets distribute about 50 syringes a year for each 
injecting drug user across the European Union. 
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, reliable 
and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisors; professionals 
and researchers working in the field of drugs; and, more broadly,  
the media and general public.
